The shot glass syringe (syriQ) and plastic syringe (TOPPAC) are suitable for ultra-low temperature storage and transportation.
Three out of four companies developing COVID-19 vaccines in clinical trials I, II, and III are supplied with SCHOTT products. SCHOTT Pharma Services provides pharmaceutical container compatibility testing for multiple formulation developments related to COVID-19. SCHOTT has supplied over 5 billion vials for COVID-19 vaccines. SCHOTT is already involved in GMP filling of syringes for COVID-19 vaccines. SCHOTT is currently executing the largest investment program in its history to rapidly expand manufacturing capacity and enhance technology at all manufacturing sites.
Inquire About This Product
basic information
SCHOTT vials enable a reduction in time to market for formulations. The syriQ syringe sets the "gold standard" for FIOLAX as a base material, exhibiting high quality levels in appearance, dimensions, and silicone oil film thickness. This results in very few free particles. SCHOTT TOPPAC contains no heavy metals or ions, has low protein adsorption, and fewer free silicone particles, which enhances pharmaceutical stability. SCHOTT TOPPAC can maintain container closure integrity (CCI) even at -80°C. SCHOTT is actively investing in expanding manufacturing capabilities for all its products. We can provide a wealth of data on the performance of temporary containers for the specific storage conditions of mRNA formulations.
Price range
Delivery Time
Applications/Examples of results
Prefilled syringe
Company information
Shot is an international technology group leading in the fields of specialty glass and glass-ceramics. With over 140 years of outstanding research and development, as well as a wealth of materials and expertise, we provide a wide range of high-quality products and intelligent solutions that contribute to our customers' success. Shot brings innovation to many industries, including home appliances, pharmaceuticals, electronics, optics, automotive, and aerospace. Shot aims to play a significant role in the lives of everyone. The core company of the group, Shot AG, is a wholly-owned subsidiary of the Carl Zeiss Foundation. Shot Japan Co., Ltd. was established in 1966 as the first sales subsidiary of the Shot Group in Asia. In February 2018, we integrated the Tokyo Sales Department, which sells optical glass, crystallized glass, thin glass, heat-resistant glass, glass tubes, optical fibers, and primary containers for pharmaceuticals, with the Mizuguchi plant, which develops and sells electronic packaging, to provide Shot's technology and products under a new structure.